Gyre Therapeutics Plunges 11.14% Despite NMPA Trial Approval

Gyre Therapeutics, Inc. (GYRE) experienced a significant drop of 11.14% in pre-market trading on April 3, 2025.

Gyre Therapeutics recently received approval from the National Medical Products Administration (NMPA) for a clinical trial. This approval allows the company to proceed with an adaptive Phase 2/3 clinical trial design, which combines dose exploration with efficacy confirmation. This development is crucial for the company's pipeline and could potentially impact its stock performance in the coming months.

In the broader market, Gyre Therapeutics has shown relative strength, with its shares rising by approximately 17% on a particular day. This indicates that despite the recent drop, the company has been performing well in the market, which could be attributed to positive investor sentiment and market dynamics.